Stapokibart provides significant improvements in signs and symptoms of atopic dermatitis irrespective of prior systemic treatment: a post-hoc analysis of a phase 3 trial

Objectives This post-hoc analysis of CM310AD005 conductedaimed to analyze the efficacy and safety of stapokibart in adults with moderate-to-severe atopic dermatitis (AD) with and without prior systemic treatment.Methods In CM310AD005, eligible patients were randomized 1:1 to receive stapokibart 600...

Descrición completa

Detalles Bibliográficos

Principais autores:	Yan Zhao, Litao Zhang, Liming Wu, Bin Yang, Jinyan Wang, Yumei Li, Qingchun Diao, Jingyi Li, Qing Sun, Xiaohong Zhu, Xiaoyong Man, Lihua Wang, Yanyan Feng, Tao Cai, Huiming Zeng, Linfeng Li, Jianyun Lu, Hong Ren, Fuqiu Li, Qianjin Lu, Xiaohua Tao, Rong Xiao, Chao Ji, Wenjie Zhao, Wei Chu, Bo Chen, Jianzhong Zhang
Formato:	Artigo
Idioma:	Inglês
Publicado:	Taylor & Francis Group 2026-12-01
Series:	Journal of Dermatological Treatment
Assuntos:	Stapokibart atopic dermatitis systemic treatment novel therapy biologics
Acceso en liña:	https://www.tandfonline.com/doi/10.1080/09546634.2026.2670890
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!